SLC6A3 and Parkinson disease: Imaging of the dopaminergic function in PD was first reported with [18F] fluorodopa ([18F]‐DOPA) PET and has been further extended in imaging studies of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) [Shen et al, 2014; Stoessl et al, 2014].